

TRANSMITTAL LETTER TO THE UNITED STATES

DESIGNATED/ELECTED OFFICE (DO/EO/US)

CONCERNING A FILING UNDER 35 U.S.C. 371

INTERNATIONAL APPLICATION NO.
PCT/EP00/05378 ✓INTERNATIONAL FILING DATE
10 June 2000 (10.06.00) ✓

ATTORNEY'S DOCKET NUMBER

RDID01007US

U.S. APPLICATION NO. (IF KNOWN, SEE 37 CFR

09/763077

PRIORITY DATE CLAIMED
18 June 1999 (18.06.99)

TITLE OF INVENTION

METHOD AND DEVICE FOR CARRYING OUT BIOCHEMICAL REACTIONS WITH A HIGH THROUGHPUT ✓

APPLICANT(S) FOR DO/EO/US

METZLER, Thomas; SCHELS, Hans; REICHHUBER, Rolf; and KLUGE, Jochen ✓

Applicant herewith submits to the United States Designated/Elected Office (DO/EO/US) the following items and other information:

1. This is a **FIRST** submission of items concerning a filing under 35 U.S.C. 371.
2. This is a **SECOND** or **SUBSEQUENT** submission of items concerning a filing under 35 U.S.C. 371.
3. This is an express request to begin national examination procedures (35 U.S.C. 371(f)) at any time rather than delay examination until the expiration of the applicable time limit set in 35 U.S.C. 371(b) and PCT Articles 22 and 39(1).
4. A proper Demand for International Preliminary Examination was made by the 19th month from the earliest claimed priority date.
5. A copy of the International Application as filed (35 U.S.C. 371 (c) (2))
 - a. is transmitted herewith (required only if not transmitted by the International Bureau).
 - b. has been transmitted by the International Bureau.
 - c. is not required, as the application was filed in the United States Receiving Office (RO/US).
6. A translation of the International Application into English (35 U.S.C. 371(c)(2)).
7. A copy of the International Search Report (PCT/ISA/210).
8. Amendments to the claims of the International Application under PCT Article 19 (35 U.S.C. 371 (c)(3))
 - a. are transmitted herewith (required only if not transmitted by the International Bureau).
 - b. have been transmitted by the International Bureau.
 - c. have not been made; however, the time limit for making such amendments has NOT expired.
 - d. have not been made and will not be made.
9. A translation of the amendments to the claims under PCT Article 19 (35 U.S.C. 371(c)(3)).
10. An oath or declaration of the inventor(s) (35 U.S.C. 371 (c)(4)). **(unexecuted)**
11. A copy of the International Preliminary Examination Report (PCT/IPEA/409).
12. A translation of the annexes to the International Preliminary Examination Report under PCT Article 36 (35 U.S.C. 371 (c)(5)).

Items 13 to 20 below concern document(s) or information included:

13. An Information Disclosure Statement under 37 CFR 1.97 and 1.98.
14. An assignment document for recording. A separate cover sheet in compliance with 37 CFR 3.28 and 3.31 is included.
15. A **FIRST** preliminary amendment. **(to follow)**
16. A **SECOND** or **SUBSEQUENT** preliminary amendment.
17. A substitute specification.
18. A change of power of attorney and/or address letter.
19. Certificate of Mailing by Express Mail
20. Other items or information:

General Appointment of Representative for U.S. Patent and Trademark Office Matters (1pp); and
Return postcard.

U.S. APPLICATION NO. (IF KNOWN SEE 37 CFR 091763077	INTERNATIONAL APPLICATION NO. PCT/EP00/05378	ATTORNEY'S DOCKET NUMBER RDID01007US		
21. The following fees are submitted..	CALCULATIONS PTO USE ONLY			
BASIC NATIONAL FEE (37 CFR 1.492 (a) (1) - (5)) :				
<input type="checkbox"/> Neither international preliminary examination fee (37 CFR 1.482) nor international search fee (37 CFR 1.445(a)(2) paid to USPTO and International Search Report not prepared by the EPO or JPO	\$970.00			
<input checked="" type="checkbox"/> International preliminary examination fee (37 CFR 1.482) not paid to USPTO but International Search Report prepared by the EPO or JPO	\$840.00			
<input type="checkbox"/> International preliminary examination fee (37 CFR 1.482) not paid to USPTO but international search fee (37 CFR 1.445(a)(2)) paid to USPTO	\$690.00			
<input type="checkbox"/> International preliminary examination fee paid to USPTO (37 CFR 1.482) but all claims did not satisfy provisions of PCT Article 33(1)-(4)	\$670.00			
<input type="checkbox"/> International preliminary examination fee paid to USPTO (37 CFR 1.482) and all claims satisfied provisions of PCT Article 33(1)-(4)	\$96.00			
ENTER APPROPRIATE BASIC FEE AMOUNT =	\$860.00			
Surcharge of \$130.00 for furnishing the oath or declaration later than months from the earliest claimed priority date (37 CFR 1.492 (e)).		<input type="checkbox"/> 20 <input type="checkbox"/> 30 \$0.00		
CLAIMS	NUMBER FILED	NUMBER EXTRA	RATE	
Total claims	- 20 =	0	x \$18.00	\$0.00
Independent claims	- 3 =	0	x \$78.00	\$0.00
Multiple Dependent Claims (check if applicable).		<input type="checkbox"/>	\$0.00	
TOTAL OF ABOVE CALCULATIONS =	\$860.00			
Reduction of 1/2 for filing by small entity, if applicable. Verified Small Entity Statement must also be filed (Note 37 CFR 1.9, 1.27, 1.28) (check if applicable).		<input type="checkbox"/> \$0.00		
SUBTOTAL =	\$860.00			
Processing fee of \$130.00 for furnishing the English translation later than months from the earliest claimed priority date (37 CFR 1.492 (f)).		<input type="checkbox"/> 20 <input type="checkbox"/> 30 + \$0.00		
TOTAL NATIONAL FEE =	\$860.00			
Fee for recording the enclosed assignment (37 CFR 1.21(h)). The assignment must be accompanied by an appropriate cover sheet (37 CFR 3.28, 3.31) (check if applicable).		<input type="checkbox"/> \$0.00		
TOTAL FEES ENCLOSED =	\$860.00			
		Amount to be: refunded \$		
		charged \$		

- A check in the amount of _____ to cover the above fees is enclosed.
- Please charge my Deposit Account No. **50-0877** in the amount of **\$860.00** to cover the above fees. A duplicate copy of this sheet is enclosed.
- The Commissioner is hereby authorized to charge any fees which may be required, or credit any overpayment to Deposit Account No. **50-0877**. A duplicate copy of this sheet is enclosed.

NOTE: Where an appropriate time limit under 37 CFR 1.494 or 1.495 has not been met, a petition to revive (37 CFR 1.137(a) or (b)) must be filed and granted to restore the application to pending status.

SEND ALL CORRESPONDENCE TO:

Kenneth J. Waite
Roche Diagnostics Corporation
9115 Hague Road, Bldg. D
P.O. Box 50457
Indianapolis, IN 46250-0457
Telephone No.: (317) 521-3104
Facsimile No.: (317) 521-2883

SIGNATURE

Kenneth J. Waite

NAME

45,189

REGISTRATION NUMBER

16 February 2001

DATE

Docket No. RDID 01007 US

PATENT

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re application of: METZLER, Thomas, et al.

Application No.: To Be Assigned Group No.: To Be Assigned

Filed: February 16, 2001 Examiner: To Be Assigned

For: METHOD AND DEVICE FOR CARRYING OUT BIOCHEMICAL REACTIONS
WITH A HIGH THROUGHPUT

Assistant Commissioner for Patents
Washington, D.C. 20231

PRELIMINARY AMENDMENT

Sir:

Please enter the following amendments prior to examination
of the above-referenced application:

IN THE CLAIMS:

Please cancel claims 1-15 as submitted originally with the present application. Please enter the following claims (claims 16 to 31) for consideration and examination. A clean copy of claims 16 to 31 is attached pursuant to 37 C.F.R. 1.121.

16. (new) A device for carrying out biochemical reactions for cell-free polypeptide biosynthesis and/or for the production of biologically active proteins, said device comprising an external housing that encloses an inner housing, said inner housing having incorporated wells and a supply chamber, wherein the wells of the inner housing each contain a producing system during the biochemical reaction, the supply chamber contains a supply liquid during the biochemical reaction and the wells of the inner housing and the supply chamber are separated by a semipermeable membrane, the inner housing having at least two wells, the lower ends of which are closed by a semipermeable membrane and the upper ends of

which protrude from the supply liquid contained in the supply chamber, connected to means for moving and incubating the producing systems and the supply liquid.

17. (new) The device of claim 16, wherein the inner housing has between 2 and about 1000 wells.
18. (new) The device of claim 16, wherein the wells have side walls that are coated with a component which specifically binds the in vitro synthesized proteins.
19. (new) The device of claim 18, wherein the wells are coated with components that are suitable for purifying polypeptides that bind to the components.
20. (new) The device of claim 18, wherein the wells are coated with streptactin, avidin or streptavidin.
21. (new) The device of claim 16, wherein the wells of the inner housing each have a volume between 50 μ l and 10 ml.
22. (new) The device of claim 16, wherein the volume of the supply solution is five to twenty-times the sum of the volumes of the wells.
23. (new) The device of claim 16, wherein the semipermeable membrane is a dialysis membrane or an ultrafiltration membrane with a pore size of 3 to 100 kDa.
24. (new) The device of claim 16 wherein the upper ends of the wells are sealed individually.
25. (new) The device of claim 16 wherein the outer housing is sealed with a closing cover.

- PCT/GB2003/003450
26. (new) The device of claim 16, wherein the wells of the inner housing are composed of blocks having the same bore geometry and having a membrane fixed between the blocks.
 27. (new) The device of claim 16, wherein the means for moving is configured such that the producing system and supply solution are mixed simultaneously.
 28. (new) The device of claim 27, wherein the mixing is achieved by a shaking or stirring element.
 29. (new) A method for carrying out one or several biochemical reactions concurrently, said method comprising utilizing a device as claimed in claim 16, wherein the supply liquid in the supply chamber is not subjected to an external applied pressure during the biochemical reaction and thus the molecular exchange between the supply chamber and the individual wells of the inner housing is essentially based on diffusion.
 30. (new) A method for carrying out one or several biochemical reactions concurrently, said method comprising utilizing a device as claimed in as claimed in 26 or 27, wherein the supply liquid and optionally the producing system in each of the wells of the inner housing are moved during the biochemical reaction by means of a magnetic stirring element.

31. (new) A kit comprising the following components: a solution comprising a substance buffering between pH 7 and 8, 150 to 400 mM potassium ions, 10 to 50 mM magnesium ions, nucleotide triphosphates, amino acids and a substance reducing sulfide groups; an energy-rich compound; a tRNA fraction; and optionally a RNA polymerase and/or a cell-free lysate.

Respectfully submitted,



Kenneth J. Waite, Reg. No. 45,189
Roche Diagnostics Corporation
9115 Hague Road, Bldg. D
P.O. Box 50457
Indianapolis, IN 46250-0457
Telephone No.: (317) 521-3104
Facsimile No.: (317) 521-2883

Date: August 30, 2001

\\\RIDNFDAT5\VOL2\CORE\IPLD\IDS\01001-01199\01007us\Preliminary Amendment.doc

- PCT/US2001/016345
16. A device for carrying out biochemical reactions for cell-free polypeptide biosynthesis and/or for the production of biologically active proteins, said device comprising an external housing that encloses an inner housing, said inner housing having incorporated wells and a supply chamber, wherein the wells of the inner housing each contain a producing system during the biochemical reaction, the supply chamber contains a supply liquid during the biochemical reaction and the wells of the inner housing and the supply chamber are separated by a semipermeable membrane, the inner housing having at least two wells, the lower ends of which are closed by a semipermeable membrane and the upper ends of which protrude from the supply liquid contained in the supply chamber, connected to means for moving and incubating the producing systems and the supply liquid.
 17. The device of claim 16, wherein the inner housing has between 2 and about 1000 wells.
 18. The device of claim 16, wherein the wells have side walls that are coated with a component which specifically binds the in vitro synthesized proteins.
 19. The device of claim 18, wherein the wells are coated with components that are suitable for purifying polypeptides that bind to the components.
 20. The device of claim 18, wherein the wells are coated with streptactin, avidin or streptavidin.
 21. The device of claim 16, wherein the wells of the inner housing each have a volume between 50 μ l and 10 ml.
 22. The device of claim 16, wherein the volume of the supply solution is five to twenty-times the sum of the volumes of the wells.

- 100-000-0000000000
23. The device of claim 16, wherein the semipermeable membrane is a dialysis membrane or an ultrafiltration membrane with a pore size of 3 to 100 kDa.
 24. The device of claim 16 wherein the upper ends of the wells are sealed individually.
 25. The device of claim 16 wherein the outer housing is sealed with a closing cover.
 26. The device of claim 16, wherein the wells of the inner housing are composed of blocks having the same bore geometry and having a membrane fixed between the blocks.
 27. The device of claim 16, wherein the means for moving is configured such that the producing system and supply solution are mixed simultaneously.
 28. The device of claim 27, wherein the mixing is achieved by a shaking or stirring element.
 29. A method for carrying out one or several biochemical reactions concurrently, said method comprising utilizing a device as claimed in claim 16, wherein the supply liquid in the supply chamber is not subjected to an external applied pressure during the biochemical reaction and thus the molecular exchange between the supply chamber and the individual wells of the inner housing is essentially based on diffusion.
 30. A method for carrying out one or several biochemical reactions concurrently, said method comprising utilizing a device as claimed in as claimed in 26 or 27, wherein the supply liquid and optionally the producing system in each of the wells of the inner housing are moved during the

biochemical reaction by means of a magnetic stirring element.

31. A kit comprising the following components: a solution comprising a substance buffering between pH 7 and 8, 150 to 400 mM potassium ions, 10 to 50 mM magnesium ions, nucleotide triphosphates, amino acids and a substance reducing sulfide groups; an energy-rich compound; a tRNA fraction; and optionally a RNA polymerase and/or a cell-free lysate.

2/RTS

09/763077
JC02 Rec'd PCT/PTO 16 FEB 2001

Roche Diagnostics GmbH

5208/0A/WO

Method and device for carrying out biochemical reactions with a high throughput

The invention concerns a method and a device for carrying out biochemical reactions especially for polypeptide biosynthesis and for the coupled in vitro transcription and translation of proteins in a cell-free system using a multi-channel dialysis device which enables the concurrent synthesis of different proteins in adequate yields under simple and reproducible conditions.

The principle of cell-free in vitro protein biosynthesis using dialysis membranes has been known for several years and essentially comprises two separate chambers (one for the reaction mixture, one for the supply solution) that are connected via a membrane with a suitable pore size. Protein synthesis takes place in the reaction chamber. The supply chamber contains a solution of all reaction components required for transcription or translation that are consumed in the reaction mixture during the process of protein biosynthesis. Due to the fact that both chambers are connected by a semipermeable membrane, consumed reaction components in the reaction chamber can be continuously replaced by new components from the supply chamber, if necessary by means of an appropriate pumping device, and consequently synthesis can be maintained over a considerably longer time period compared to a static system i.e. a corresponding reaction that takes place in a reaction vessel that is not subdivided. Corresponding methods for cell-free in

PCT/DE00/0039260

vitro biosynthesis based on the continuous flow or the continuous exchange principle are described for example in US 5,478,730, EP 0 593 757 and by Spirin et al. in Science vol. 242, 1988 p. 1162-1164.

The synthesis system used according to the patent document US 5,478,730 for example contains a source of DNA or mRNA which codes for the polypeptide. In addition the cell-free synthesis system essentially contains ribosomes, tRNA, amino acids, ATP, GTP, UTP and CTP. The transcription of DNA and the translation of mRNA with the aid of tRNA results in the production of the respective polypeptide together with low molecular weight by-products and waste materials. These can pass into a supply space through a semi-permeable membrane which segregates the space containing the synthesis system from the supply space. The supply space contains a liquid which acts as a supply medium containing in particular ATP, GTP and amino acids. These components are supplied to the synthesis system through the semipermeable membrane in order to replenish materials consumed during the biosynthesis reaction. Passage through the semipermeable membrane is possible since their molecular weight is below the cut-off limit. At the same time products of the biochemical reaction and other substances with a molecular weight below the cut-off of the barrier pass from the reaction space into the supply space. According to the US patent document 5,478,730 the semipermeable membrane is for example an ultrafiltration membrane in the form of hollow fibre membranes.

The US patent document 5,478,730 contains extensive additional information on suitable compositions for the synthesis system and the supply liquid. To this extent

the present invention makes reference to the prior art and in particular this US patent document and the literature references cited therein. The contents thereof are incorporated into the present application by way of reference.

The European Patent 0 593 757 describes the application of coupled transcription and translation for corresponding in vitro biosynthesis methods in which essentially an RNA polymerase was additionally added to the reaction mixture.

In addition various dialysis devices and membranes are known. The main distinction is between so-called single tube and multi-channel designs. The previously described and commercially available dialysis materials that are suitable for in vitro protein biosynthesis are exclusively based on the single tube principle (e.g. EP 99 91 01 418.4; Promega Notes 1997). These dialysis aids do not enable a high throughput or the concurrent synthesis of different proteins especially without complicated purification procedures or other measures such as the denaturation of proteins that are synthesized as inclusion bodies. An additional disadvantage of dialysis devices based on the single tube principle is that they are technically difficult to operate and time consuming.

Furthermore microtitre plates containing wells which are provided with a porous membrane at the lower end are commercially available. So-called multi-channel versions are only suitable for cell culture applications or for filtration or rebuffering processes (e.g. ultra-filtration membranes from Milipore; Slide-A-Lyzer[®] MINI

T00000000000000000000000000000000

Dialysis Unit from Pierce). However, these multi-channel devices do not allow an exchange of liquids of different concentrations that are used for in vitro transcription or in vitro translation which is why they are unsuitable for in vitro protein synthesis applications with for example a continuous supply and removal of components.

Hence the object of the invention is to provide a method and device which enable biochemical reactions to be carried out with high efficiency and at the same time in a simple and very reproducible manner.

The object is achieved by a device for carrying out biochemical reactions, in particular for cell-free polypeptide biosynthesis and/or for the production of biologically active proteins with a native structure composed of an external housing which encloses an inner housing with incorporated wells and a supply chamber, wherein the wells of the inner housing each contain a producing system during the biochemical reaction, the supply chamber contains a supply liquid and the wells of the inner housing and the supply chamber are separated by a semipermeable membrane characterized in that the inner housing has at least two wells the lower ends of which are closed by a semipermeable membrane and the upper ends of which protrude out of the supply liquid contained in the supply chamber, and is connected to means for moving and incubating the producing systems and the supply liquid.

Suitable external housings for the invention are for example bowl-shaped or cylindrical vessels that are able to hold liquids and in which it is possible to insert and optionally fix a geometrically smaller inner

T000E80 "Z"00E9260

housing. The inner housing can have any external dimensions which correspond in size and shape to the external housing. For example round, rectangular or quadratic designs are suitable for the external housing with volumes of ca. 10 ml to several litres. It is advantageous when the geometry of the inner housing conforms to that of the outer housing as far as possible. Furthermore the inner housing can have a microtitre plate (MTP) format. This enables a simple automation and acceleration of the individual operating steps.

The inner housing has one or several wells preferably two or more e.g. six, eight, twelve, 24, 48, 64, 96, 384 etc. However, in principle it is also possible to use an inner housing for the device according to the invention with several hundred to thousand or more wells for example in the form of blocks or microtitre plates. The wells are usually made of an inert material such as polyethylene or polypropylene and can be designed for volumes of ca. 50 μ l up to several millilitres i.e. in the order of magnitude of 10 ml. Conical wells whose lower end is closed with a semipermeable membrane e.g. a dialysis membrane with a pore size of 3 to 100 kilodaltons are advantageous. In principle all conventional dialysis and ultrafiltration membranes of a suitable pore size can be used for the invention. Dialysis membranes with a pore size of ca. 10 to 14 kilodaltons have proven to be particularly suitable. This enables the separation especially of interfering low-molecular inhibitory substances that are formed during the *in vitro* biosynthesis. Either each individual well or all wells together can be provided with a cap closure or foil to seal the upper openings of the wells i.e. the part of the wells of the inner housing which protrude

from the supply liquid contained in the supply chamber. Alternatively a closing cap can also be attached to seal the entire outer housing.

A further preferred embodiment of the inner housing of the device according to the invention is composed of a layer of blocks with a plurality of drilled holes. A further flat block having the same hole geometry is located above a first block. A filter or semipermeable membrane is placed between the two blocks. The second flatter block is suitable for collecting by-products or waste materials which hence do not reach the supply chamber or only to a very slight extent. The end result is an inner housing with wells which are each divided by a membrane into a reaction space and a so-called second supply or dialysis chamber. Closing both sides of the inner housing with dialysis membranes, on the one hand, doubles the area available for exchange and, on the other hand, results in their being hardly any change in the volume of the samples. A particular advantage of this embodiment is that there is considerably less or delayed accumulation of non-utilizable components in the supply liquid sustaining the in vitro protein synthesis which further increases the efficiency of the protein synthesis.

Furthermore it has proven to be advantageous to coat the walls of the individual wells of the inner housing with components that specifically bind the proteins and peptides synthesized in vitro. Suitable components are especially those that are suitable for the purification of tag-containing proteins. The protein synthesized in vitro in the wells (containing tag) can thus be bound in this manner to the coated microtitre plate and subsequently be directly purified, optionally after

washing with suitable buffers or be eluted in a pure form by suitable reagents. An example of a so-called protein tag is Strep-Tag II (8AA sequence, see DE 42 37 113) which can be bound either to the N- or C-terminus of the in vitro synthesized protein. Streptactin, streptavidin or avidin can for example be used as coating substances. Processes for coating suitable surfaces are known to a person skilled in the art. Alternatively it is also possible to separate the synthesized, tag-carrying proteins from the reaction mixture of the individual wells by means of appropriately coated glass or magnetic particles.

The inventive device is additionally equipped with a stirring or shaking device in order to ensure an adequate movement or diffusion of the reaction solution(s) and the supply solution. It has proven to be advantageous to place a stirring element in the form of a magnetic stirrer in the supply chamber and optionally in each individual well in which a reaction proceeds. This ensures a simultaneous mixing of the producing system, of the mixtures in the individual wells and of the surrounding supply solution. In order to ensure a constant temperature during the biochemical reaction - which is usually between 20° and 37°C - the entire device is most simply placed completely in a closable incubator or held under a temperature-controlled incubation hood. Moreover combined shaking or stirring and thermostating devices can be used according to the invention. The mixing of the reaction mixture(s) and of the supply solution can thus occur simultaneously with shaking or stirring movements of a suitable frequency and can be carried out over a long period at a constant temperature.

As a rule it is sufficient to incubate the reaction mixture(s) over a period of ca. 20 hours in order to obtain the desired proteins or peptides in adequate yields. Ca. 25 to 50 µg protein/250 µl reaction solution in a well which corresponds to a concentration of 100 to 200 µg/ml can already be reached after ca. 6 hours depending on the protein to be synthesized, the optimization of the individual process parameters and the exact composition of the supply solution. Moreover longer incubation times can lead to correspondingly better yields, for example concentrations of up to 500 µg/ml were obtained for GFP (green fluorescent protein).

A further preferred embodiment of the invention is when the volume of the supply solution is determined according to the number or the total volume of the wells of the inner housing. As a guideline according to the invention the volume of the supply solution is equal to the sum of the number of wells and the volume per well multiplied by a factor of 10.

The composition of the supply solution essentially corresponds to that of corresponding solutions of the prior art for cell-free in vitro biosynthesis. Moreover a person skilled in the art will know that supply solutions for cell-free protein synthesis are subject to certain conventional optimization measures which especially depend on the type and quality of the ribosomal fraction i.e. whether for example a eukaryotic or prokaryotic system is used as the basis for the cell-free in vitro biosynthesis. In addition it has proven to be advantageous for the supply solution to contain an agent that reduces sulfide groups and - in the case of an E. coli-based lysate - an inhibitor for E. coli

polymerases and optionally one or several suitable bactericidal substances.

A particularly preferred supply solution according to the invention for a coupled transcription/translation reaction contains in a suitable buffer system such as e.g. Hepes, ca. 150 to 400 mM potassium ions, ca. 10 to 50 mM magnesium ions, adequate amounts of the four nucleotide triphosphates (ATP, CTP, GTP and UTP) and all naturally occurring amino acids, ca. 20 to 80 mM acetyl phosphate, dithiothreitol as a reagent reducing sulfide groups and optionally EDTA, glycerol, one or several bactericidal substances such as e.g. rifampicin or sodium azide and preferably - in the case of a ribosomal fraction derived from E. coli - an RNA polymerase inhibitor such as rifampicin to deactivate E. coli polymerases. A typical reaction mixture for a transcription/translation reaction contains the appropriate components in comparable amounts to the supply solution. In addition a reaction mixture according to the invention contains the respective eukaryotic or prokaryotic ribosomal fraction such as e.g. an E. coli lysate, the DNA coding for the desired protein in the form of a plasmid, ca. 1 to 10 U/ μ l of an RNA polymerase, ca. 200 to 800 μ g/ml of a tRNA and optionally further auxiliary substances such as RNase inhibitors.

An additional subject matter of the invention is a method for carrying out one and in particular several concurrent biochemical reactions using the device according to the invention wherein the supply liquid in the supply chamber is not subjected to an external applied pressure during the biochemical reaction and thus the molecular exchange between the supply chamber

and the solutions of the individual wells of the inner housing is essentially based on diffusion.

The method according to the invention and the device suitable therefore are particularly suitable for automated applications with a high synthesis throughput.

The invention additionally concerns a reaction kit for carrying out in vitro protein syntheses or for the coupled in vitro transcription and translation of proteins in a cell-free system using a corresponding device. The kit is essentially composed of a supply solution and a solution for the reaction mixtures. The solutions can be present in a liquid form as well as in a freeze-dried state. The supply solution essentially comprises a substance buffering between pH 7 and 8, ca. 150 to 400 mM potassium ions, ca. 10 to 50 mM magnesium ions, nucleotide triphosphates (ATP, CTP, GTP and UTP), ca. 20 different amino acids and a substance reducing sulfide groups. Moreover additional auxiliary substances such as stabilizers or inhibitors for preventing undesired reactions can be added to the supply solution. The solution for the reaction mixtures corresponds to the solution of the aforementioned supply solution and additionally contains a cell-free lysate i.e. a prokaryotic or eukaryotic ribosomal fraction, tRNA and an RNA polymerase the origin of which is different from that of the ribosomal fraction. According to the invention it is preferable to not admix the components of the reaction mixture solutions that are different from the components of the supply solution until shortly before carrying out the reaction i.e. they are each present in separate vessels. This applies correspondingly to the supply solution as well as to the energy-rich compounds that are to be added to the

FOODS 2009/50

reaction solution such as acetyl phosphate. This further improves the storage life and the adaptability of the reaction kit.

The invention is further illustrated by the following examples.

Example 1:

The method according to the invention for cell-free protein biosynthesis is elucidated in more detail in the following using an *E. coli* lysate and two model proteins (CAT and GFP):

Cell-free protein biosynthesis is carried out in the form of a coupled transcription and translation in which the mRNA to be transcribed is coded on a plasmid whose gene sequence contains a promoter for a viral RNA polymerase (e.g. SP6, T3 or T7 RNA polymerase).

The mRNA transcribed in vitro is translated into the corresponding protein with the aid of the *E. coli* lysate present in the coupled system.

A) Reaction components:

Plasmids: pM-GFP or pIVEX-GFP contain the sequence for the green fluorescent protein from *Aequorea victoria* in the form of a mutant GFPcycle3 (27 kilodaltons) (*Nature Biotechnology*, 1996, 14, p. 315-319); the coding region of the GFPcycle3 mutant was cloned into pTU58 instead of the wild type GFP sequence (*Science*, 1994, **263**, 802).

pHM-CAT contains the sequence for the chloroamphenicol acetyl transferase protein (22.5 kilodaltons).

Construction: An insert (NcoI-BamHI) from pCAT3 (Promega) was inserted into pHM19 (FU Berlin, "Instit. f. Biochemie", Dr. Stiege).

E. coli S30 lysate: The lysate was prepared from an E. coli A19 strain by a modified method according to Zubay (Annu. Rev. Genet. 7, 267, 1973).

Lysate buffer: 100 mM Hepes-KOH pH 7.6/30°C, 14 mM magnesium acetate, 60 mM potassium acetate, 0.5 mM dithiothreitol

Composition of the reaction and supply solution:

Transcription/translation reaction mixture:

185 M potassium acetate, 15 mM magnesium acetate, 4 % glycerol, 2.06 mM ATP, 1.02 mM CTP, 1.64 mM GTP, 1.02 mM UTP, 257 μ M of each amino acid (a total of 20), 10.8 μ g/ml folic acid, 1.03 mM EDTA, 100 mM Hepes-KOH pH 7.6/30°C, 1 μ g/ml rifampicin, 0.03 % sodium azide, 40 mM acetyl phosphate, 480 μ g/ml tRNA from E. coli MRE600, 2 mM dithiothreitol, 10 mM MESNA (mercaptoethane sulfonic acid), 70 mM potassium hydroxide, 0.1 U/ μ l RNase inhibitor, 15 μ g/ml plasmid, 220 μ l/ml E. coli A19 lysate, 2 U/ μ l T7 RNA polymerase.

Supply solution:

185 mM potassium acetate, 15 mM magnesium acetate, 4 % glycerol, 2.06 mM ATP, 1.02 mM CTP, 1.64 mM GTP, 1.02 mM

UTP, 257 μ M of each amino acid (a total of 20), 10.8 μ g/ml folic acid, 1.03 mM EDTA, 100 mM Hepes-KOH pH 7.6/30°C, 1 μ g/ml rifampicin, 0.03 % sodium azide, 40 mM acetyl phosphate, 2 mM dithiothreitol, 10 mM MESNA (mercaptoethane sulfonic acid), 70 mM potassium hydroxide, lysate buffer as described above containing 220 μ l/ml.

B) Device:

A multi-channel dialyzer in the form of a microtitre plate was used in the example described here. The bottoms of the individual wells of the microtitre plate were each provided with a dialysis membrane with a cut off volume of 10 kilodaltons. The maximum reaction volume per well was 200 μ l. The housing for the supply solution had a capacity of 200 ml.

C) Movement, cover:

Shaking device: Flow laboratories, type: Titertek® with a shaking frequency step 4.5

Incubation hood: Edmund Bühler, type: TH25, at a temperature of 30°C

D) Procedure:

Separate reaction mixtures of the above-mentioned composition were pipetted:

- 1) for the expression of GFP containing pM-GFP or pIVEX-GFP
- 2) for the expression of CAT containing pHM-CAT

A volume of 8.4 ml was prepared for each mixture and 200 μ l thereof was pipetted into a total of 40 wells (0.4 ml as excess) i.e. 40 wells per mixture and protein.

200 ml supply solution of the above-mentioned composition was pipetted for the supply chamber, i.e. a common supply solution was used for both reaction mixtures.

After sealing the microtitre plate with an adhesive foil, the device was attached to the shaking device which was located under the incubation hood.

After adjusting the shaking frequency and the incubation temperature of 30°C, the reaction mixtures were incubated for 20 hours.

E) Evaluation:

1) Expression of GFP:

The samples were measured using a spectral fluorimeter from the Kontron Company, type: TEGIMENTA, SFM25. Excitation was at a wavelength of 395 nm. Emission rate at 580 to 430 nm. Emission maximum is at 510 nm.

rGFP (recombinant GFP) from Roche Diagnostics, Catalogue number 1814524 was used as the standard.

The samples were diluted 1:200 with the lysate buffer and the standard was diluted to 1 μ g/ml and 2 μ g/ml.

Table 1:

10 values from the 40 obtained (which were all in the same range) are shown as a representative selection.

Figure 1:

Graphic evaluation of the values shown in table 1 in $\mu\text{g GFP/ml}$ reaction solution in the selected wells.

Table 1:

well number	1	2	3	4	5	6	7	8	9	10
$\mu\text{g GFP/ml reaction volume}$	366	365	362	356	369	371	365	367	361	365

2) Expression of CAT:

The samples were measured by HPLC analysis using the instrument type: LKB 2150.

A CAT enzyme from Roche Diagnostics, Catalogue number 1485156 was used as a standard.

Table 2:

10 volumes from the 40 obtained (which were all in the same range) are shown as a representative selection.

Figure 2:

Graphic evaluation of the values shown in table 2 in $\mu\text{g CAT/ml}$ reaction solution in the selected wells.

Table 2:

well number	1	2	3	4	5	6	7	8	9	10
μg CAT/ml reaction solution	233	230	233	235	228	231	227	228	229	232

Claims

1. Device for carrying out biochemical reactions, in particular for cell-free polypeptide biosynthesis and/or for the production of biologically active proteins with a native structure composed of an external housing which encloses an inner housing with incorporated wells and a supply chamber, wherein the wells of the inner housing each contain a producing system during the biochemical reaction, the supply chamber contains a supply liquid during the biochemical reaction and the wells of the inner housing and the supply chamber are separated by a semipermeable membrane characterized in that the inner housing has at least two wells the lower ends of which are closed by a semipermeable membrane and the upper ends of which protrude from the supply liquid contained in the supply chamber, and is connected to means for moving and incubating the producing systems and the supply liquid.
2. Device as claimed in claim 1, characterized in that the inner housing has between 2 and ca. 1000 wells.
3. Device as claimed in claim 1 or 2, characterized in that the side walls of the wells are coated with a component which specifically binds the in vitro synthesized proteins.
4. Device as claimed in claim 3, characterized in that the wells are coated with components that are suitable for purifying polypeptides that bind to the components.

5. Device as claimed in claim 3 or 4, characterized in that the wells are coated with streptactin, avidin or streptavidin.
6. Device as claimed in one of the claims 1-5, characterized in that the wells of the inner housing each have a volume between 50 μ l and 10 ml.
7. Device as claimed in one of the claims 1-6, characterized in that the volume of the supply solution is five to twenty-times the sum of the volumes of the wells.
8. Device as claimed in one of the claims 1-7, characterized in that the semipermeable membrane is a dialysis membrane or an ultrafiltration membrane with a pore size of 3 to 100 kDa.
9. Device as claimed in one of the claims 1-8, characterized in that in order to seal the openings of the wells of the inner housing that face upwards, each well is individually or all wells together are provided with a cap closure or foil or a closing cover is present to seal the outer housing.
10. Device as claimed in one of the claims 1-9, characterized in that the wells of the inner housing are composed of blocks having the same bore geometry and a membrane fixed between the blocks.

11. Device as claimed in one of the claims 1-10, characterized in that the movement means is such that the producing system and supply solution are mixed simultaneously.
12. Device as claimed in claim 11, characterized in that the mixing is achieved by a shaking or stirring element.
13. Method for carrying out one or several biochemical reactions concurrently by means of a device as claimed in one of the claims 1-12, characterized in that the supply liquid in the supply chamber is not subjected to an external applied pressure during the biochemical reaction and thus the molecular exchange between the supply chamber and the individual wells of the inner housing is essentially based on diffusion.
14. Method as claimed in claim 13 in conjunction with claim 11 or 12, characterized in that the supply liquid and optionally the producing system in each of the wells of the inner housing are moved during the biochemical reaction by means of a magnetic stirring element.
15. Kit composed of the following components
- 1) a solution which contains a substance buffering between pH 7 and 8, 150 to 400 mM potassium ions, 10 to 50 mM magnesium ions, nucleotide triphosphates, amino acids and a substance reducing sulfide groups,

- 2) an energy-rich compound,
- 3) a tRNA fraction and optionally
- 4) a RNA polymerase and/or
- 5) a cell-free lysate.

4000EBC0 "Z/0E/0E/0E/0

Abstract


Device, method and kit for carrying out biochemical reactions, in particular for cell-free polypeptide biosynthesis composed of an external housing which encloses an inner housing with incorporated wells and a supply chamber, wherein the wells of the inner housing each contain a producing system during the biochemical reaction, the supply chamber contains a supply liquid during the biochemical reaction and the wells of the inner housing and the supply chamber are separated by a semipermeable membrane characterized in that the inner housing has at least two wells the lower ends of which are closed by a semipermeable membrane and the upper ends of which protrude from the supply liquid contained in the supply chamber, and is connected to means for moving and incubating the producing systems and to the supply liquid.

100E50 220E9260

09/763077

1 / 2


Figure 1



09/763077

2 / 2

Figure 2



Docket No. RDID01007US

Declaration and Power of Attorney For Patent Application

English Language Declaration

As a below named inventor, I hereby declare that:

My residence, post office address and citizenship are as stated below next to my name,

I believe I am the original, first and sole inventor (if only one name is listed below) or an original, first and joint inventor (if plural names are listed below) of the subject matter which is claimed and for which a patent is sought on the invention entitled

METHOD AND DEVICE FOR CARRYING OUT BIOCHEMICAL REACTIONS WITH A HIGH THROUHPUT

the specification of which

(check one)

is attached hereto.

was filed on February 16, 2001 as United States Application No. or PCT International Application Number 09/763,077

and was amended on _____
(if applicable)

I hereby state that I have reviewed and understand the contents of the above identified specification, including the claims, as amended by any amendment referred to above.

I acknowledge the duty to disclose to the United States Patent and Trademark Office all information known to me to be material to patentability as defined in Title 37, Code of Federal Regulations, Section 1.56.

I hereby claim foreign priority benefits under Title 35, United States Code, Section 119(a)-(d) or Section 365(b) of any foreign application(s) for patent or inventor's certificate, or Section 365(a) of any PCT International application which designated at least one country other than the United States, listed below and have also identified below, by checking the box, any foreign application for patent or inventor's certificate or PCT International application having a filing date before that of the application on which priority is claimed.

Prior Foreign Application(s)

Priority Not Claimed

<u>PCT/EP00/05378 ✓</u>	<u>PCT</u>	<u>10</u>	<input type="checkbox"/>
<u>(Number) 99 111 762.3</u>	<u>(Country) Europe</u>	<u>6 June 2000</u>	<input type="checkbox"/>
<u>(Number)</u>	<u>(Country)</u>	<u>(Day/Month/Year Filed) 18 June 1999 ✓</u>	<input type="checkbox"/>
<u>(Number)</u>	<u>(Country)</u>	<u>(Day/Month/Year Filed)</u>	<input type="checkbox"/>
		<u>(Day/Month/Year Filed)</u>	<input type="checkbox"/>

I hereby claim the benefit under 35 U.S.C. Section 119(e) of any United States provisional application(s) listed below:

(Application Serial No.)

(Filing Date)

(Application Serial No.)

(Filing Date)

(Application Serial No.)

(Filing Date)

I hereby claim the benefit under 35 U. S. C. Section 120 of any United States application(s), or Section 365(c) of any PCT International application designating the United States, listed below and, insofar as the subject matter of each of the claims of this application is not disclosed in the prior United States or PCT International application in the manner provided by the first paragraph of 35 U.S.C. Section 112, I acknowledge the duty to disclose to the United States Patent and Trademark Office all information known to me to be material to patentability as defined in Title 37, C. F. R., Section 1.56 which became available between the filing date of the prior application and the national or PCT International filing date of this application:

(Application Serial No.)

(Filing Date)

(Status)

(patented, pending, abandoned)

(Application Serial No.)

(Filing Date)

(Status)

(patented, pending, abandoned)

(Application Serial No.)

(Filing Date)

(Status)

(patented, pending, abandoned)



I hereby declare that all statements made herein of my own knowledge are true and that all statements made on information and belief are believed to be true; and further that these statements were made with the knowledge that willful false statements and the like so made are punishable by fine or imprisonment, or both, under Section 1001 of Title 18 of the United States Code and that such willful false statements may jeopardize the validity of the application or any patent issued thereon.



POWER OF ATTORNEY: As a named inventor, I hereby appoint the following attorney(s) and/or agent(s) to prosecute this application and transact all business in the Patent and Trademark Office connected therewith. (*list name and registration number*)

7-
Kenneth J. Waite, Reg. No. 45,189
 D. Michael Young, Reg. No. 33,819
 Brent A. Harris, Reg. No. 39,215
 Richard T. Knauer, Reg. No. 35,575
 Marilyn L. Amick, Reg. No. 30,444
 Michelle Neff, Reg. No. P-47,817
 Jill L. Woodburn, Reg. No. 39,874

Send Correspondence to: Kenneth J. Waite
Roche Diagnostics Corporation
9115 Hague Road, Bldg. D, P.O. Box 50457
Indianapolis, IN 46250-0457

Direct Telephone Calls to: (*name and telephone number*)
Kenneth J. Waite, Telephone No. (317) 521-3104

Full name of sole or first inventor <u>METZLER, Thomas</u>	Date
Sole or first inventor's signature 	 25.04.01
Residence <u>Maistrasse 57, D-80337 Munich, Germany DEX</u>	
Citizenship <u>German</u>	
Post Office Address (same as residence)	
	

2-01 Full name of second inventor, if any <u>SCHELS, Hans</u>	Date
Second inventor's signature 	 19.05.01
Residence <u>Behamstrasse 21, D-80687 Munich, Germany DEX.</u>	
Citizenship <u>German</u>	
Post Office Address (same as residence)	
	

3-80
Full name of third inventor, if any

REICHHUBER, Rolf

Third inventor's signature

Rolf Reichhuber ✓

Date

23.04.01

Residence

Am Burgholz 4a, D-82377 Penzberg, Germany *DEX*

Citizenship

German ✓

Post Office Address

(same as residence)

4-80
Full name of fourth inventor, if any

KLUGE, Jochen

Fourth inventor's signature

Jochen Kluge

✓

Date

1.5.01

Residence

Scheidegger Strasse 31, D-81476 Munich, Germany *DEX*

Citizenship

German ✓

Post Office Address

(same as residence)

5-80
Full name of fifth inventor, if any

Fifth inventor's signature

Date

Residence

Citizenship

Post Office Address

6-80
Full name of sixth inventor, if any

Sixth inventor's signature

Date

Residence

Citizenship

Post Office Address